- Home
- EXEL vs MGM Comparison
EXEL vs MGM Comparison
Compare EXEL & MGM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXEL | MGM |
|---|---|---|
| Founded | 1994 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 9.2B |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | EXEL | MGM |
|---|---|---|
| Price | $43.87 | $34.12 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 21 | 15 |
| Target Price | ★ $46.60 | $42.58 |
| AVG Volume (30 Days) | 2.7M | ★ 5.1M |
| Earning Date | 02-10-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.95 | N/A |
| EPS | ★ 2.78 | 0.76 |
| Revenue | $2,320,126,000.00 | ★ $17,537,683,000.00 |
| Revenue This Year | $14.86 | $1.16 |
| Revenue Next Year | $14.93 | $1.92 |
| P/E Ratio | ★ $15.36 | $44.99 |
| Revenue Growth | ★ 6.98 | 1.72 |
| 52 Week Low | $32.38 | $25.30 |
| 52 Week High | $49.62 | $41.32 |
Technical Indicators
Market Signals| Indicator | EXEL | MGM |
|---|---|---|
| Relative Strength Index (RSI) | 51.45 | 42.86 |
| Support Level | $40.92 | $34.77 |
| Resistance Level | $44.28 | $38.14 |
| Average True Range (ATR) | 1.48 | 1.51 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 70.53 | 22.64 |
Price Performance
Historical ComparisonAbout EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About MGM MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 37,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Park MGM, Luxor, New York-New York, and Bellagio. The Strip contributed approximately 59% of total EBITDAR in 2024. MGM also owns US regional assets, which represented a low 20s share of 2024 EBITDAR (MGM's Macao EBITDAR was 21% of the total in 2024). MGM's US sports and i-gaming operations are currently a high-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM China casinos with a second property that opened on the Cotai Strip in early 2018. We estimate MGM will open a resort in Japan in 2030.